2024-517378-22-00招募中2 期
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC)
Fondazione Centro Nazionale Di Adroterapia Oncologica3 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2024年11月26日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 27
- 试验地点
- 3
- 主要终点
- Objective response rate (ORR) according to RECIST, assessed at least 8 weeks after CIRT
研究概览
简要总结
To estimate the effect, in terms of clinical response, of immunotherapy associating carbon ion treatment in the palliative setting across different malignancies, for which immunotherapy is currently the standard of care.
详细描述
This is a multicenter, open label, non-randomized phase II clinical trial aiming to assess the feasibility and the clinical activity of adding CIRT to ICIs in cancer patients that have obtained a disease stability (SD) with pembrolizumab administered as per standard of care. At study entry, hypofractionated CIRT will be delivered to one measurable lesion previously untreated with local approaches.CIRT will be performed at Fondazione CNAO, Pavia
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Histologic confirmation of malignancies under treatment with single agent anti-PD1/PDL1 immunotherapy per clinical practice (see cohort specific inclusion criteria) with immune checkpoint inhibitors approved by Italian national drug regulatory agencies (Agenzia Italiana del Farmaco, AIFA)
- •Having a disease stability as assessed by AIFA monitoring sheet
- •Presence of at least 2 measurable target lesions, of which at least one to be followed up as per RECIST and one suitable for CIRT
- •Willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other requirements of the study
- •Females and males, 18 years of age or older (no upper limit for age)
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- •Subjects must have measurable disease by CT or MRI per RECIST 1.1
排除标准
- •Patients treated with chemo-immunotherapy associations
- •Any immune-related CTCAE grade 4 adverse event, before study entry
- •Any CTCAE grade ≥3 immune-related adverse event observed within 3 weeks prior to CIRT start
- •Presence of metal prostheses or any other condition to prevent adequate imaging for identification of the target volume and calculation of the dose
- •Loco-regional conditions not allowing hadron therapy (e.g. active infections in RT target region)
- •Prisoners or subjects who are involuntarily incarcerated
- •Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness (e.g. infectious disease)
- •Patients treated with immunotherapy combinations (e.g. subjects treated with anti-CTLA4 + anti-PD1/PDL1 are excluded)
- •Patients receiving immunotherapy within clinical trials
- •Patients receiving off-label immunotherapy or within expanded access programs or as compassionate use
- •Patients with high tumor burden defined as > 10 lesions and/or sum of diameters > 19 cm
- •Patients with distant metastases only located in the CNS are excluded
- •Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
- •Patients with autoimmune diseases (ADs), including local and systemic collagen-vascular (CVD) and inflammatory bowel diseases (IBD)
- •Previous RT, regardless of energy, on the metastatic site selected to be irradiated
结局指标
主要结局
Objective response rate (ORR) according to RECIST, assessed at least 8 weeks after CIRT
Objective response rate (ORR) according to RECIST, assessed at least 8 weeks after CIRT
Toxicity according to CTCAE version 5.0
Toxicity according to CTCAE version 5.0
次要结局
- progression-free survival (PFS)
- overall survival (OS)
- objective response of the metastatic lesion treated with CIRT
- disease control rate (DCR) according to RECIST, defined as ORR+SD
- objective response rate (ORR) according to irRECIST
- percentage of patients with disease progression as best response
研究者
Federica Serra
Scientific
Fondazione Centro Nazionale Di Adroterapia Oncologica
研究点 (3)
Loading locations...
相似试验
已完成
不适用
Immuno-Oncology Database and BioregistryMalignancyImmune System DiseasesAutoimmune DiseasesNCT04656873UNC Lineberger Comprehensive Cancer Center32
招募中
不适用
Montreal Immune-Related Adverse Events (MIRAE) StudyImmune System DisorderInflammatory ReactionAutoimmune DiseasesCancerNCT05139706Sir Mortimer B. Davis - Jewish General Hospital1,000
已完成
2 期
AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiSMyocarditisNCT05195645Assistance Publique - Hôpitaux de Paris21
已完成
不适用
Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced MalignancyPalliativeAdvanced CancerImmunotherapyRadiation TherapyNCT03042156University Health Network, Toronto42
Unknown
不适用
Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse EventsCancerNCT04169503University Hospital, Caen17,562